Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial

Trial Profile

Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms PACE
  • Most Recent Events

    • 08 Sep 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the 2017 Rodman & Renshaw Conference.
    • 25 Aug 2017 According to a RespireRx Pharmaceuticals media release, on june 6, 2017 results from this trial were presented at the Sleep 2017 conference.
    • 14 Jun 2017 According to a RespireRx Pharmaceuticals media release, this study was fully funded by the National Heart, Lung and Blood Institute of the National Institutes of Health.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top